MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 81 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $935,418 | +31.5% | 116,201 | +77.3% | 0.00% | – |
| Q2 2023 | $711,580 | -33.1% | 65,523 | -57.5% | 0.00% | – |
| Q1 2023 | $1,063,697 | +58.9% | 154,159 | -8.3% | 0.00% | – |
| Q4 2022 | $669,321 | -55.7% | 168,171 | -26.0% | 0.00% | – |
| Q3 2022 | $1,511,000 | +586.8% | 227,219 | +398.5% | 0.00% | – |
| Q2 2022 | $220,000 | -85.0% | 45,584 | -71.0% | 0.00% | – |
| Q1 2022 | $1,468,000 | -18.4% | 156,949 | +3.5% | 0.00% | – |
| Q4 2021 | $1,800,000 | -33.8% | 151,569 | -36.6% | 0.00% | -100.0% |
| Q3 2021 | $2,721,000 | -35.4% | 239,125 | +1.8% | 0.00% | 0.0% |
| Q2 2021 | $4,214,000 | +18.3% | 234,872 | +2.1% | 0.00% | 0.0% |
| Q1 2021 | $3,561,000 | +363.7% | 229,994 | +265.2% | 0.00% | – |
| Q4 2020 | $768,000 | +88.2% | 62,976 | +98.5% | 0.00% | – |
| Q3 2020 | $408,000 | – | 31,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |